Zentalis Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
ZNTL$1.80+3.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands)
| Three Months Ended June 30, 2026 | ||||||
|---|---|---|---|---|---|---|
| Common · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalEquity | ||||||
| Shares · Amount | ||||||
| Balance at March 31, 2026 | 71,156 | $71 | $1,409,466 | $(50) | $(1,226,807) | $182,680 |
| Share-based compensation expense | — | — | 3,215 | — | — | 3,215 |
| Other comprehensive loss | — | — | — | (28) | — | (28) |
| Issuance of common stock in connection with restricted stock unit vesting, net | 477 | 1 | (1) | — | — | — |
| Issuance of common stock upon exercise of options, net | 36 | — | 65 | — | — | 65 |
| Net loss | — | — | — | — | (42,286) | (42,286) |
| Balance at June 30, 2026 | 71,669 | $72 | $1,412,745 | $(78) | $(1,269,093) | $143,646 |
| Six Months Ended June 30, 2026 | ||||||
|---|---|---|---|---|---|---|
| Common · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalEquity | ||||||
| Shares · Amount | ||||||
| Balance at December 31, 2025 | 69,086 | $69 | $1,407,394 | $196 | $(1,191,455) | $216,204 |
| Share-based compensation expense | — | — | 6,412 | — | — | 6,412 |
| Other comprehensive loss | — | — | — | (274) | — | (274) |
| Issuance of common stock in connection with restricted stock unit vesting, net | 2,301 | 3 | (1,457) | — | — | (1,454) |
| Issuance of common stock upon exercise of options, net | 57 | — | 101 | — | — | 101 |
| Shares issued under employee stock purchase plan | 225 | — | 295 | — | — | 295 |
| Net loss | — | — | — | — | (77,638) | (77,638) |
| Balance at June 30, 2026 | 71,669 | $72 | $1,412,745 | $(78) | $(1,269,093) | $143,646 |
| Three Months Ended June 30, 2025 | ||||||
|---|---|---|---|---|---|---|
| Common · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income · AccumulatedDeficit · TotalEquity | ||||||
| Shares · Amount | ||||||
| Balance at March 31, 2025 | 71,951 | $72 | $1,397,626 | $358 | $(1,102,674) | $295,382 |
| Share-based compensation expense | — | — | 6,286 | — | — | 6,286 |
| Other comprehensive loss | — | — | — | (299) | — | (299) |
| Issuance of common stock in connection with restricted stock unit vesting, net | 184 | — | — | — | — | — |
| Net loss | — | — | — | — | (26,874) | (26,874) |
| Balance at June 30, 2025 | 72,135 | $72 | $1,403,912 | $59 | $(1,129,548) | $274,495 |
| Six Months Ended June 30, 2025 | ||||||
|---|---|---|---|---|---|---|
| Common · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income · AccumulatedDeficit · TotalEquity | ||||||
| Shares · Amount | ||||||
| Balance at December 31, 2024 | 71,282 | $71 | $1,390,952 | $558 | $(1,054,395) | $337,186 |
| Share-based compensation expense | — | — | 12,772 | — | — | 12,772 |
| Other comprehensive loss | — | — | — | (499) | — | (499) |
| Issuance of common stock in connection with restricted stock unit vesting, net | 714 | 1 | (1) | — | — | — |
| Shares issued under employee stock purchase plan | 139 | — | 189 | — | — | 189 |
| Net loss | — | — | — | — | (75,153) | (75,153) |
| Balance at June 30, 2025 | 72,135 | $72 | $1,403,912 | $59 | $(1,129,548) | $274,495 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.